Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MGNX
MGNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MGNX News
MacroGenics Stock Surpasses Analyst Target Price
Mar 11 2026
NASDAQ.COM
MacroGenics Antibody Drug Progress Expected in 2026
Mar 10 2026
stocktwits
MacroGenics Reports FY Earnings Beat Expectations
Mar 09 2026
seekingalpha
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
MacroGenics to Participate in Upcoming Investor Conferences
Feb 26 2026
Newsfilter
MacroGenics Faces FDA Partial Hold on Key Clinical Trial
Feb 24 2026
seekingalpha
MacroGenics Faces Partial Clinical Hold on LINNET Study
Feb 24 2026
Benzinga
MacroGenics Faces Partial Clinical Hold on LINNET Study
Feb 24 2026
NASDAQ.COM
MacroGenics Faces Partial Clinical Hold on LINNET Study
Feb 23 2026
Newsfilter
Incyte's Cancer Therapy Zynyz Receives EMA Endorsement for New Indication
Jan 30 2026
seekingalpha
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
Nov 13 2025
NASDAQ.COM
MacroGenics Revenue Doubles in Q2
Aug 14 2025
NASDAQ.COM
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates
Aug 13 2025
NASDAQ.COM
MacroGenics signs financial deal with Sagard for retifanlimab
Jun 10 2025
SeekingAlpha
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
Jun 10 2025
Newsfilter
4 Analysts Assess Macrogenics: What You Need To Know
May 20 2025
Benzinga
Show More News
